Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II study of TQB2922 injection with chemotherapy ± bevacizumab in RAS/BRAF wild-type metastatic colorectal cancer
CTR20252141Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2922 in colorectal cancer (CRC), sponsored by Nanjing Shunxin Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
tqb2922
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20252141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252141.